Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Thermo Fisher Scientific    TMO

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Thermo Fisher Scientific : OMass Announces Publication in Nature Methods

share with twitter share with LinkedIn share with facebook
05/18/2020 | 08:15am EDT

Oxford - OMass Therapeutics ('OMass'), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, announces the publication of a novel, highly enabling native mass spectrometry approach that marks a significant technical advance in the field.

In this study OMass scientists, in collaboration with researchers from Oxford University, the Karolinska Institute and Thermo Fisher Scientific, describe the development of a top-down mass spec methodology. The development allows definition of the lipidome/metabolome in contact with the protein complex of interest and was supported by MD simulations carried out at the University of Southampton. The development of the new tribrid Orbitrap MS instrument was the result of OMass and Oxford university scientists working closely with a team at Thermo Fisher Scientific. The article was published in the 5th May 2020 print issue of Nature Methods.

Joint OMass Founders, Dr Idlir Liko and Dr Hsin-Yung Yen, Director of Technology and Director of Biology respectively, worked in collaboration with Dr Joseph Gault, OMass consultant, and Prof. Dame Carol Robinson's research group at the University of Oxford.

'This study not only highlights the exciting potential of novel native MS technologies but also demonstrates our continued commitment to technology development and pushing the boundaries of what is possible with our platform,' said Ali Jazayeri, Chief Scientific Officer, OMass Therapeutics. 'Application of these advances to our drug discovery efforts, in combination with additional in-house developments such as proprietary native MS compatible chemical libraries and probes, will certainly enhance the capabilities of our platform and create further differentiation and competitive advantage. Such technical advances require significant team work and collaboration and we are delighted to continue to work alongside Professor Dame Carol Robinson and her talented team at Oxford University as well as working with leading MS manufacturers.'

'Nature Methods selects publications based on their ability to demonstrate novel approaches to challenging and high-interest problems in basic biology research, enabling researchers to explore new corners of biology,' commented Professor Dame Carol Robinson, Founder & Scientific Advisor, OMass Therapeutics. 'This publication thereby recognises the significant potential of high definition, native mass spectrometry to drug development.'

Contact:

Julia Wilson

Tel: +44 (0)7818 430877

Email: juliawilsonuk@gmail.com

About OMass Therapeutics

OMass is harnessing native mass spectrometry and other biophysical technologies to drive drug discovery in high definition. The company's suite of proprietary technologies delivers superior resolution to traditional pharmacology assays enabling a clearer, more detailed picture of how a putative ligand engages a protein target assessing binding and function in parallel. The additional information obtained in the OMass assays can reveal new biology even at well-studied receptors and the cell-free system is unbiased for different ligand chemistries unmasking chemical space of high therapeutic potential inaccessible to cell-based assays. The company is building a pipeline of small molecule therapeutics to bring life-changing benefits to patients suffering from immunology and genetic disorders. OMass is backed by Syncona Ltd Oxford Sciences Innovation and Oxford University.

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
Latest news on THERMO FISHER SCIENTIFIC
07/02THERMO FISHER SCIENTIFIC : Launches New MAS Omni Infectious Disease Quality Cont..
AQ
06/23THERMO FISHER SCIENTIFIC : Schrodinger in Collaboration with Thermo Fisher Scien..
DJ
06/17THERMO FISHER SCIENTIFIC : iSPA Workflow Helps Pharmaceutical Companies Bring Ne..
AQ
06/12THERMO FISHER SCIENTIFIC : Ex-dividend day for
FA
06/11THERMO FISHER SCIENTIFIC INC. : Entry into a Material Definitive Agreement, Crea..
AQ
06/10THERMO FISHER SCIENTIFIC : to Co-develop a Global Companion Diagnostic for Low-g..
AQ
06/10Coronavirus Makes AR's Potential a Reality for Chip Makers
DJ
06/09THERMO FISHER SCIENTIFIC : Extends NanoDrop One/OneC Spectrophotometer to FDA-Re..
AQ
06/09THERMO FISHER SCIENTIFIC : Highlights Growing Capacity for Biologics, Cell and G..
AQ
05/28THERMO FISHER SCIENTIFIC : and CSL Enter Strategic Partnership
AQ
More news
Financials (USD)
Sales 2020 25 696 M - -
Net income 2020 3 539 M - -
Net Debt 2020 12 387 M - -
P/E ratio 2020 42,6x
Yield 2020 0,23%
Capitalization 145 B 145 B -
EV / Sales 2019
EV / Sales 2020 6,11x
Nbr of Employees 75 000
Free-Float 90,5%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 365,53 $
Last Close Price 365,89 $
Spread / Highest target 14,8%
Spread / Average Target -0,10%
Spread / Lowest Target -25,9%
EPS Revisions
Managers
NameTitle
Marc N. Casper Chairman, President & Chief Executive Officer
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Scott M. Sperling Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERMO FISHER SCIENTIFIC12.63%144 509
DANAHER CORPORATION17.07%127 037
INTUITIVE SURGICAL, INC.-1.81%67 694
ILLUMINA, INC.12.47%54 846
BOSTON SCIENTIFIC CORPORATION-21.76%50 413
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.63.11%49 997